Patients given Meridia had a16 percent increased risk of heart problems such as heart attack or stroke compared to those given a placebo, the study showed. 研究表明,与接受安慰剂的患者相比,接受西布曲明患者例如心脏病发作和中风等心脏问题风险增加16%。
There was no increased risk of death, although Meridia patients also saw an increase in blood pressure and heart rate, it said. 它指出,尽管接受西布曲明患者还可以出现血压和心率增加,但是死亡风险并不增加。
"We continue to believe that there are appropriate and identifiable patients that derive benefit" from Meridia, said Eugene Sun, the company's vice president of global pharmaceutical development. “我们继续相信有合适的和可以确认的患者获得益处”自西布曲明,该公司全球制药发展副主席EugeneSun说。
Meridia is not a big seller for the Illinois-based drugmaker, but has drawn attention to the controversial area of prescription diet drugs ever since its U.S.approval in1997. 西布曲明不是伊利诺州药品生产者大的销售者,但是自1997年在美国获得批准开始,它就吸引处方减肥药的争议。
Final data from the so-called SCOUT study, published on Wednesday, showed Meridia increases the risk of heart attacks and strokes in patients who already have heart disease. 星期三发表的所谓SCOUT研究的最终数据表明西布曲明增加已患心脏病的患者的心脏病发作和中风的风险。
The company, along with the study's authors, said Meridia should still be used, just not by people with heart problems. 公司与研究作者一起说西布曲明仍然可以被使用,只是不能被伴有心脏疾病的人使用。
To those hoping for a clear-as-a-bell signal from today's FDA advisory committee meeting on Abbott's weight-loss drug Meridia: sorry. 对于那些希望自今天FDA顾问委员会关于雅培减肥药西布曲明的会议得到一个非常清楚信号的人:对不起的。